Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berdazimer sodium - SB 206 - Ligand Pharmaceuticals

Next Previous
Drug Profile

Berdazimer sodium - SB 206 - Ligand Pharmaceuticals

Alternative Names: Berdazimer gel; Berdazimer gel 10.3%; MAP3-NONOate - SB-206; NI-MC101; NVN-1000-SB-206-Novan; NVN1000-SB206; SB-206; ZELSUVMI

Latest Information Update: 14 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Novan Inc; Sato
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Free radicals; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Molluscum contagiosum
  • Phase II Viral infections
  • Discontinued Genital warts; Human papillomavirus infections; Staphylococcal infections

Most Recent Events

  • 14 Jul 2025 Planned Prescription Drug User Fee Act (PDUFA) date for Molluscum contagiosum (In adults, In adolescents, In children, In the elderly, In infants) in USA (Topical) is 2024-01-05
  • 10 Jul 2025 Launched for Molluscum contagiosum (In adults, In adolescents, In children, In the elderly, In infants) in USA (Topical)
  • 02 Jul 2025 Novan announces intention to launch Berdazimer sodium - SB 206 (ZELSUVMI TM) for Molluscum contagiosum in July 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top